Dyskinesia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Dyskinesia - Pipeline Review, H1 2016', provides an overview of the Dyskinesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Dyskinesia - The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects - The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Dyskinesia Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Dyskinesia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Dyskinesia Overview 8 Therapeutics Development 9 Pipeline Products for Dyskinesia - Overview 9 Pipeline Products for Dyskinesia - Comparative Analysis 10 Dyskinesia - Therapeutics under Development by Companies 11 Dyskinesia - Therapeutics under Investigation by Universities/Institutes 13 Dyskinesia - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Dyskinesia - Products under Development by Companies 17 Dyskinesia - Products under Investigation by Universities/Institutes 20 Dyskinesia - Companies Involved in Therapeutics Development 21 Adamas Pharmaceuticals, Inc. 21 Addex Therapeutics Ltd 22 Advicenne Pharma 23 Amarantus Bioscience Holdings, Inc. 24 Astraea Therapeutics, LLC 25 Bionomics Limited 26 Catalyst Biosciences, Inc. 27 Catalyst Pharmaceutical Partners, Inc. 28 Clevexel Pharma SAS 29 Contera Pharma ApS 30 EpiVax, Inc. 31 Heptares Therapeutics Limited 32 Hua Medicine Ltd. 33 Integrative Research Laboratories Sweden AB 34 Ipsen S.A. 35 Merz Pharma GmbH & Co. KgaA 36 MitoDys Therapeutics Limited 37 Neurim Pharmaceuticals Ltd 38 Neurocrine Biosciences, Inc. 39 Neurolixis Inc. 40 Osmotica Pharmaceutical Corp. 41 Otsuka Holdings Co., Ltd. 42 Phenomenome Discoveries, Inc. 43 Revance Therapeutics, Inc. 44 Sage Therapeutics, Inc. 45 Santhera Pharmaceuticals Holding AG 46 SciFluor Life Sciences, LLC 47 SOM Innovation Biotech SL 48 Synchroneuron Inc. 49 Teva Pharmaceutical Industries Limited 50 Dyskinesia - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Combination Products 52 Assessment by Target 53 Assessment by Mechanism of Action 56 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 (dextromethorphan + quinidine sulfate) - Drug Profile 62 A2M-13677 - Drug Profile 64 abobotulinumtoxin A - Drug Profile 65 abobotulinumtoxin A next generation - Drug Profile 67 acamprosate calcium SR - Drug Profile 68 amantadine hydrochloride ER - Drug Profile 70 amantadine hydrochloride ER - Drug Profile 72 AT-127 - Drug Profile 73 AT-326 - Drug Profile 74 AT-403 - Drug Profile 75 befiradol - Drug Profile 76 CPP-115 - Drug Profile 78 CVXL-0107 - Drug Profile 80 daxibotulinumtoxin A - Drug Profile 81 deutetrabenazine ER - Drug Profile 83 dipraglurant ER - Drug Profile 85 dipraglurant IR - Drug Profile 86 Drug for Dyskinesia - Drug Profile 88 Drugs for Dyskinesia - Drug Profile 89 Drugs for Tardive Dyskinesia - Drug Profile 90 eltoprazine - Drug Profile 91 fipamezole - Drug Profile 94 HTL-14242 - Drug Profile 96 IRL-790 - Drug Profile 97 JM-010 - Drug Profile 98 MLR-1019 - Drug Profile 100 MRZ-8676 - Drug Profile 101 NBI-640756 - Drug Profile 102 Neu-120 - Drug Profile 103 Neu-240 - Drug Profile 104 onabotulinumtoxin A - Drug Profile 105 PEUN-3 - Drug Profile 106 PPI-1011 - Drug Profile 107 RT-002 - Drug Profile 108 SAGE-217 - Drug Profile 109 sepranolone - Drug Profile 110 SK-609 - Drug Profile 113 Small Molecule for Dyskinesia - Drug Profile 114 Small Molecule for Dyskinesia and Hyperkinesia - Drug Profile 115 Small Molecules for CNS Disorders - Drug Profile 116 Small Molecules for Neurodegenerative Disease - Drug Profile 117 Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 118 Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 119 Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 120 SOM-3355 - Drug Profile 121 TC-8831 - Drug Profile 122 tetrabenazine - Drug Profile 123 valbenazine tosylate - Drug Profile 124 VU-0431316 - Drug Profile 126 Dyskinesia - Recent Pipeline Updates 127 Dyskinesia - Dormant Projects 164 Dyskinesia - Discontinued Products 167 Dyskinesia - Product Development Milestones 168 Featured News & Press Releases 168 Appendix 178 Methodology 178 Coverage 178 Secondary Research 178 Primary Research 178 Expert Panel Validation 178 Contact Us 178 Disclaimer 179
List of Tables
Number of Products under Development for Dyskinesia, H1 2016 13 Number of Products under Development for Dyskinesia - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Development by Companies, H1 2016 (Contd..2) 23 Products under Investigation by Universities/Institutes, H1 2016 24 Dyskinesia - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 25 Dyskinesia - Pipeline by Addex Therapeutics Ltd, H1 2016 26 Dyskinesia - Pipeline by Advicenne Pharma, H1 2016 27 Dyskinesia - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 28 Dyskinesia - Pipeline by Astraea Therapeutics, LLC, H1 2016 29 Dyskinesia - Pipeline by Bionomics Limited, H1 2016 30 Dyskinesia - Pipeline by Catalyst Biosciences, Inc., H1 2016 31 Dyskinesia - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 32 Dyskinesia - Pipeline by Clevexel Pharma SAS, H1 2016 33 Dyskinesia - Pipeline by Contera Pharma ApS, H1 2016 34 Dyskinesia - Pipeline by EpiVax, Inc., H1 2016 35 Dyskinesia - Pipeline by Heptares Therapeutics Limited, H1 2016 36 Dyskinesia - Pipeline by Hua Medicine Ltd., H1 2016 37 Dyskinesia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016 38 Dyskinesia - Pipeline by Ipsen S.A., H1 2016 39 Dyskinesia - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 40 Dyskinesia - Pipeline by MitoDys Therapeutics Limited, H1 2016 41 Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 42 Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H1 2016 43 Dyskinesia - Pipeline by Neurolixis Inc., H1 2016 44 Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp., H1 2016 45 Dyskinesia - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 46 Dyskinesia - Pipeline by Phenomenome Discoveries, Inc., H1 2016 47 Dyskinesia - Pipeline by Revance Therapeutics, Inc., H1 2016 48 Dyskinesia - Pipeline by Sage Therapeutics, Inc., H1 2016 49 Dyskinesia - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2016 50 Dyskinesia - Pipeline by SciFluor Life Sciences, LLC, H1 2016 51 Dyskinesia - Pipeline by SOM Innovation Biotech SL, H1 2016 52 Dyskinesia - Pipeline by Synchroneuron Inc., H1 2016 53 Dyskinesia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 54 Assessment by Monotherapy Products, H1 2016 55 Assessment by Combination Products, H1 2016 56 Number of Products by Stage and Target, H1 2016 58 Number of Products by Stage and Mechanism of Action, H1 2016 61 Number of Products by Stage and Route of Administration, H1 2016 63 Number of Products by Stage and Molecule Type, H1 2016 65 Dyskinesia Therapeutics - Recent Pipeline Updates, H1 2016 131 Dyskinesia - Dormant Projects, H1 2016 168 Dyskinesia - Dormant Projects (Contd..1), H1 2016 169 Dyskinesia - Dormant Projects (Contd..2), H1 2016 170 Dyskinesia - Discontinued Products, H1 2016 171
List of Figures
Number of Products under Development for Dyskinesia, H1 2016 13 Number of Products under Development for Dyskinesia - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Products, H1 2016 20 Assessment by Monotherapy Products, H1 2016 55 Number of Products by Top 10 Targets, H1 2016 57 Number of Products by Stage and Top 10 Targets, H1 2016 57 Number of Products by Top 10 Mechanism of Actions, H1 2016 60 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 60 Number of Products by Routes of Administration, H1 2016 62 Number of Products by Stage and Routes of Administration, H1 2016 62 Number of Products by Molecule Types, H1 2016 64 Number of Products by Stage and Top 10 Molecule Types, H1 2016 64
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the demRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmaceRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.